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Guidelines are systematically developed statements to
assist practitioner and patient decisions about appropri-
ate health care for specific clinical circumstances [1].
They concern often complex diagnostic or therapeutic
strategies with several possible interventions at each
step, where each intervention has to be assessed and
compared with other possible interventions at short and
long term for efficacy, effectiveness, efficiency (optional),
side effects, quality of life, acceptability, benefits/risks
ratio. For common diseases, the methodology and the
different steps of the guidelines development process
have been established and apply the principles of evi-
dence-based-medicine. Developing guidelines for rare
diseases (RD) is more difficult, because of the lack of
sound evidence, surveys of clinical practices, data about
patients’ opinion and ethical reflexions [2].
During the 1st French national plan for rare diseases,
HAS (French National Authority for Health) was
mandated to define a method to develop guidelines for RD
- which are called PNDS (National Diagnostic and Treat-
ment Protocols) in France - and coordinate their writing
with the RD centres of reference [3]. A PNDS constitutes
a best practice reference document for healthcare profes-
sionals in charge of rare disease patients. Based on it, HAS
drawn up a “List of Procedures and Services” (LAP), which
includes all of the diagnostic tests, drugs, medical devices
and services that appear justified in providing care to a
patient. From 2005 to now, only 47 PNDS were published
and 8 are on-going, because the development method is
complex and expertise is scarce; 135 new PNDS projects
are pending. In the 2nd French plan for rare diseases it
was proposed to define a simplified method for developing
the PNDSs, in order to speed up their production, by
using the protocols already developed by the RD reference
centres, incorporating and adapting recommendations
devised by foreign groups of experts when appropriate;
and setting criteria for prioritisation of the PNDS produc-
tion. This process is on its way.
Orphanet has launched the production of emergency
guidelines, written by centres of reference in collaboration
with emergency department practitioners, patient organi-
sations, and validated by a special reading group with
members of emergency medicine learned societies. They
include a short description of the disease, recommenda-
tions for immediate care, transport and orientation, before
getting to the emergency ward, recommendations for the
emergency ward (complications to be looked for, diagnos-
tic and therapeutic particularities, drugs interactions,
anaesthesia), recommendations for patient’s and family’s
comfort, list of contacts 24h/24 [4].
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